Alvotech
ALVO
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arth… read more
Healthcare
Drug Manufacturers—Specialty & Generic
3 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$3.47
Price-1.98%
-$0.07
1Y
Price
Market Cap
$1.081b
Small
Price/Earnings 3y Avg5y Avg
15.1x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+3.2%
EBITDA Margin-4.6%
Net Profit Margin-65.4%
Free Cash Flow Margin+3.2%
EBITDA Margin-4.6%
Net Profit Margin-65.4%
Free Cash Flow MarginRevenue
$571.162m
+16.6%
1y CAGR+154.1%
3y CAGR+147.0%
5y CAGREarnings
$69.533m
+130.0%
1y CAGR+60.2%
3y CAGR-56.4%
5y CAGREPS
$0.21
+124.1%
1y CAGR+65.0%
3y CAGR+53.7%
5y CAGRBook Value
-$176.763m
$1.409b
Assets$1.586b
Liabilities$1.282b
DebtDebt to Assets
91.0%
17.6x
Debt to EBITDAFree Cash Flow
-$113.452m
+61.4%
1y CAGR+26.7%
3y CAGR+11.5%
5y CAGRNo items found.
Press Releases
Statements and updates from the company